Ask AI

Multiple Myeloma

Share

Program Content

Activities

DURGA 1
DURGA-1: Phase Ib/II Study of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-Cell Therapy, in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

CAMMA 1 Updated Analysis
CAMMA 1: Updated Safety, Efficacy, and Biomarker Analyses From Phase I Study of Cevostamab + Pomalidomide + Dexamethasone in BCMA1-Naive RRMM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Cilta cel for Standard Risk RRMM
Extended Efficacy and Safety Outcomes With Ciltacabtagene Autoleucel (Cilta-cel) in Patients With R/R MM With Standard-Risk Cytogenetics
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Cevostamab Consolidation in RR MM
Phase II Trial of Cevostamab Consolidation After Anti-BCMA CAR T-Cell Therapy in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

iMMagine 1
iMMagine-1 Update: Phase II Study of D-Domain BCMA-Directed CAR T-Cell Therapy, Anitocabtagene Autoleucel, in R/R MM
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner